Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial

2021144 citationsJournal Article

Authors

Good health and well-beingPartnerships for the goals

Published in: The Lancet. Gastroenterology & hepatology

Volume 6, Issue 8, pp. 649-658

Field-Weighted Citation Impact: 12.66